Drug Database
TO

torasemide (torasemide PR / Britomar / Sutril)

✓ Approved

Takeda · SLC12A1 · Small Molecule

What is torasemide?

torasemide is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namestorasemide PR, Britomar, Sutril
CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetSLC12A1, SLC12A2
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

torasemide acts on 2 molecular targets:

SLC12A1solute carrier family 12 member 1 (NKCC2, BSC1)
SLC12A2solute carrier family 12 member 2 (PPP1R141, hNKCC1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

torasemide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedJACC. Case reports2026-07-10

Long-Term Hemodynamic Stabilization With TTR-Stabilizing Therapy and Pressure-Guided Management in ATTR Cardiomyopathy.

Sedighi Jamschid J, Unsöld Bernhard B, Boettger Priyanka P, Herrmann Ester J EJ et al.

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is underdiagnosed in heart failure with preserved ejection fraction. Although disease-modifying therapies slow the disease progression, their long-term hemodynamic effects remain unclear. An 82-year-old woman with recently confirmed wild-type ATTR-CM and NYHA functional class III heart failure with preserved ejection fraction underwent pulmonary artery pressure (PAP) sensor implantation for recurrent heart failure hospitalizations shortly after the initiation of transthyretin-stabilizing therapy in 2022. During 3.5 years of follow-up, diastolic PAP decreased from 21 to 7 mm Hg, accompanied by torasemide reduction from 60 to 10 mg/day. In this case, the combination of transthyretin-stabilizing therapy and PAP-guided follow-up was associated with sustained hemodynamic improvement and clinical stability. However, the independent contribution of pulmonary artery monitoring cannot be determined from a single uncontrolled observation. Remote PAP-guided management may support disease-modifying treatment in selected patients with ATTR-CM.

PMID 42429736
Read full article →
PubMedFarmaceuticos comunitarios2026-07-01

Pharmacotherapeutic Optimization in a Polymedicated Patient Through Coordinated Pharmaceutical Intervention: A Community Pharmacy Case Report.

Vera Peña A A, Dévora Gutiérrez S S, Morales Marrero C C, Vitória Figueiredo I I et al.

Case presentation: An 82-year-old woman, polymedicated (receiving chronic treatment with ten active pharmaceutical ingredients) and independent for basic activities of daily living, was evaluated. Following a hospital consultation due to fatigue and electrolyte disturbances, a family member attended the community pharmacy (CP) with the clinical documentation, requesting support to improve adherence and pharmacotherapy follow-up through repackaging using a Multicompartment Compliance Aid (MCA) [1]. Case study and evaluation: During the initial interview, several Drug-Related Problems (DRPs) were identified: inappropriate dosage of olmesartan/hydrochlorothiazide, combination of diuretics with kaliuretic effect (torasemide and hydrochlorothiazide), prolonged use of omeprazole without current indication, lack of recent laboratory monitoring in the management of hypercholesterolemia, untreated cognitive impairment, and unnecessary prescription of paracetamol. These DRPs posed a risk of generating Negative Outcomes associated with Medication (NOMs) within the three categories established by the Community Pharmacy Pharmaceutical Care Forum: necessity, effectiveness, and safety (2). Intervention: From the community pharmacy, and in coordination with the family and the primary care team, the dosage regimen of olmesartan/hydrochlorothiazide was adjusted, torasemide and paracetamol were discontinued, the atorvastatin dose was modified according to recent laboratory results, and, following specialist recommendation, memantine 10 mg/day together with cognitive stimulation measures was initiated. Results: Serum potassium levels normalized, adequate blood pressure control was achieved, the lipid profile was optimized, and therapeutic adherence improved through the use of the MCA. The patient reported better sleep quality, absence of pain, and greater functional autonomy. Conclusions: Coordinated intervention between community pharmacy, family environment, and primary care allowed optimization of pharmacotherapy, reduction of overmedication, and improvement in quality of life. This case illustrates the clinical and social value of Professional Pharmaceutical Care Services when developed within an integrated care framework, reinforcing the strategic role of community pharmacy in the comprehensive care of older polymedicated patients within a person-centered healthcare model.

PMID 42382139
Read full article →
PubMedJournal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology2026-06-02

Clinical findings and survival time in dogs with myxomatous mitral valve disease at the American College of Veterinary Internal Medicine stage D.

Oricco S S, Crosara S S, Mazzoldi C C, Apolloni I I et al.

Data on dogs with end-stage myxomatous mitral valve disease (MMVD) are sparse. This study aimed to describe the clinical findings and survival time of dogs with MMVD at the American College of Veterinary Internal Medicine (ACVIM) stage D. Dogs with MMVD receiving a total daily dosage of furosemide >8 mg/kg/day, or the equivalent dosage of torasemide, were retrospectively searched. Signalment, clinical, echocardiographic, electrocardiographic, laboratory, therapeutic, and outcome data were retrieved. A statistical analysis was performed to assess the entire population and compare specific subgroups of dogs based on their treatment protocols. Sixty-one dogs were included. At the time of study inclusion, left-sided congestive heart failure, pulmonary hypertension, and arrhythmias were documented in 38 of 49 (77.5%), 23 of 61 (37.7%), and 18 of 61 (29.5%) dogs, respectively. The median time needed to progress from the ACVIM stage C to D was 245 days (144-376 days). After diagnosis of stage D, the median survival time for cardiac-related death was 155 days (103-259 days). When comparing dogs receiving furosemide or torasemide, there were no significant differences in median survival time (P=0.47), serum sodium concentration (P=0.554), or serum chloride concentration (P=0.638). However, dogs receiving torasemide had higher serum creatinine (P=0.025) and lower potassium concentrations (P=0.005). The limitations of this study included the retrospective study design and heterogeneous treatment protocols. This study provides novel data on the clinical characteristics and survival expectations of dogs with MMVD at the ACVIM stage D.

PMID 42225449
Read full article →
PubMedKardiologia polska2026-05-21

N-terminal pro-B-type natriuretic peptide reference and cut-off values should be adjusted to patient's age in clinical practice - results of the PolSenior 2 national representative survey.

Stefański Adrian A, Solnica Bogdan B, Wierucki Łukasz Ł, Jagiełło Kacper K et al.

According to the guidelines of the European Society of Cardiology and AmericanHeart Association, natriuretic peptides can be used as an initial diagnostic test, especially whenechocardiography is not immediately available. The problem, however, is the lack of precise dataon reference values for natriuretic peptide levels, especially in the elderly. Purpose of this study was to assess the reference values of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in elderly patients. The PolSenior 2 study conducted from 2018 to 2020 included 5983 people aged 60+ years. People who had increased NT-proBNP level with diagnosed heart failure, atrial fibrillation,advanced kidney disease, hyperthyroidism inflammation, or were receiving eplerenone, spironolactone,furosemide, torasemide, or anticoagulants were excluded. Finally, 2981 people were includedin the analysis. The respondents were divided into age groups covering 10-year ranges, and theNT-proBNP values were analyzed. The mean age of subjects was 71.6 ± 8 years, with 51.6% being women. Only in theyoungest age group (60-69 years) there were significant differences in NT-proBNP values betweenwomen and men (median 93 [52-162] pg/ml vs. 62 [35-116] pg/ml, respectively, P <0.001). In eachsubsequent (older) age group, the level of NT-proBNP was significantly higher than in the previousone - 134 (73-260) pg/ml in respondents aged 70-79 years, 231 (121-418) pg/ml in the 80-89 yearold age group, and 446 (288-766) in respondents aged 90+ years. The level of NT-proBNP increases significantly with age, and the assessment of NT-proBNPlevel should be age adjusted accordingly. Using NT-proBNP cut-off points among elderly patientsmay lead to unnecessary diagnostics and treatment.

PMID 42165689
Read full article →
PubMedActa chimica Slovenica2026-04-01

Differential pulse anoding voltammetric determination of torasemide using carbon paste electrode.

Zayed Sayed I M SIM, Habib Ibrahim H I IHI

Torasemide electrochemical behavior at a carbon paste electrode was investigated and optimized using cyclic and differential pulse voltammetry in 0.04 mol/L Britton-Robinson (BR) buffer pH 2.8. Cyclic voltammetry showed that the oxidation process was irreversible and primarily controlled by diffusion. The responses of differential pulse were linear over the torasemide concentration range of 0.35-4.13 µg/mL, with detection and quantification limits of 0.110 and 0.367 µg/mL, respectively. The suggested voltammetric method was successful in detecting torasemide in its pharmaceutical preparation (Torsamolex 20 mg tablets) as well as in spiked urine matrix, demonstrating its suitability for pharmaceutical quality control and potential applications in clinical analysis.

PMID 41918421
Read full article →
PubMedEuropean journal of hospital pharmacy : science and practice2026-03-27

Analysis of a serious adverse reaction of rhabdomyolysis precipitated by a possible interaction of methylprednisolone with atorvastatin: a case report.

Liu Jiajia J, Mao Min M, Cai Meiyu M, Yang Zanzhang Z

A man in his 80s had been taking atorvastatin for 2 months for hyperlipidaemia. Due to the recurrence of nephrotic syndrome, methylprednisolone, torasemide, benidipine and atorvastatin were prescribed after admission to hospital. While his dyspnoea and oedema improved with diuretic therapy, the patient reported significant muscle soreness 8 days after starting the combined atorvastatin and methylprednisolone. Simultaneously, creatine kinase and myoglobin levels increased significantly. The temporal correlation between the drug combination and symptom onset, coupled with rapid clinical and biochemical improvement after atorvastatin discontinuation, supported a diagnosis of rhabdomyolysis due to a potential drug-drug interaction between atorvastatin and methylprednisolone, likely exacerbated by hypoproteinaemia. This case highlights the need for clinicians and pharmacists to be vigilant for such drug-drug interactions, particularly in patients with predisposing conditions like hypoproteinaemia.

PMID 41887741
Read full article →

+391 more articles available with a free account

Sign up free to view all articles →

Ask about torasemide